AIMS/HYPOTHESIS: Excessive ectopic lipid deposition contributes to impaired insulin action in peripheral tissues and is considered an important link between obesity and type 2 diabetes mellitus. Acetyl-CoA carboxylase 2 (ACC2) is a key regulatory enzyme controlling skeletal muscle mitochondrial fatty acid oxidation; inhibition of ACC2 results in enhanced oxidation of lipids. Several mouse models lacking functional ACC2 have been reported in the literature. However, the phenotypes of the different models are inconclusive with respect to glucose homeostasis and protection from diet-induced obesity. METHODS: Here, we studied the effects of pharmacological inhibition of ACC2 using as a selective inhibitor the S enantiomer of compound 9c ([S]-9c). Selectivity was confirmed in biochemical assays using purified human ACC1 and ACC2. RESULTS: (S)-9c significantly increased fatty acid oxidation in isolated extensor digitorum longus muscle from different mouse models (EC(50) 226 nmol/l). Accordingly, short-term treatment of mice with (S)-9c decreased malonyl-CoA levels in skeletal muscle and concomitantly reduced intramyocellular lipid levels. Treatment of db/db mice for 70 days with (S)-9c (10 and 30 mg/kg, by oral gavage) resulted in improved oral glucose tolerance (AUC -36%, p < 0.05), enhanced skeletal muscle 2-deoxy-2-[(18)F]fluoro-D-glucose (FDG) uptake, as well as lowered prandial glucose (-31%, p < 0.01) and HbA(1c) (-0.7%, p < 0.05). Body weight, liver triacylglycerol, plasma insulin and pancreatic insulin content were unaffected by the treatment. CONCLUSIONS/ INTERPRETATION: In conclusion, the ACC2-selective inhibitor (S)-9c revealed glucose-lowering effects in a mouse model of diabetes mellitus.
AIMS/HYPOTHESIS: Excessive ectopic lipid deposition contributes to impaired insulin action in peripheral tissues and is considered an important link between obesity and type 2 diabetes mellitus. Acetyl-CoA carboxylase 2 (ACC2) is a key regulatory enzyme controlling skeletal muscle mitochondrial fatty acid oxidation; inhibition of ACC2 results in enhanced oxidation of lipids. Several mouse models lacking functional ACC2 have been reported in the literature. However, the phenotypes of the different models are inconclusive with respect to glucose homeostasis and protection from diet-induced obesity. METHODS: Here, we studied the effects of pharmacological inhibition of ACC2 using as a selective inhibitor the S enantiomer of compound 9c ([S]-9c). Selectivity was confirmed in biochemical assays using purified humanACC1 and ACC2. RESULTS:(S)-9c significantly increased fatty acid oxidation in isolated extensor digitorum longus muscle from different mouse models (EC(50) 226 nmol/l). Accordingly, short-term treatment of mice with (S)-9c decreased malonyl-CoA levels in skeletal muscle and concomitantly reduced intramyocellular lipid levels. Treatment of db/db mice for 70 days with (S)-9c (10 and 30 mg/kg, by oral gavage) resulted in improved oral glucose tolerance (AUC -36%, p < 0.05), enhanced skeletal muscle 2-deoxy-2-[(18)F]fluoro-D-glucose (FDG) uptake, as well as lowered prandial glucose (-31%, p < 0.01) and HbA(1c) (-0.7%, p < 0.05). Body weight, liver triacylglycerol, plasma insulin and pancreatic insulin content were unaffected by the treatment. CONCLUSIONS/ INTERPRETATION: In conclusion, the ACC2-selective inhibitor (S)-9c revealed glucose-lowering effects in a mouse model of diabetes mellitus.
Authors: Yu Gui Gu; Moshe Weitzberg; Richard F Clark; Xiangdong Xu; Qun Li; Nathan L Lubbers; Yi Yang; David W A Beno; Deborah L Widomski; Tianyuan Zhang; T Matthew Hansen; Robert F Keyes; Jeffrey F Waring; Sherry L Carroll; Xiaojun Wang; Rongqi Wang; Christine H Healan-Greenberg; Eric A Blomme; Bruce A Beutel; Hing L Sham; Heidi S Camp Journal: J Med Chem Date: 2007-02-14 Impact factor: 7.446
Authors: Martin Torriani; Bijoy J Thomas; Elkan F Halpern; Megan E Jensen; Daniel I Rosenthal; William E Palmer Journal: Radiology Date: 2005-08 Impact factor: 11.105
Authors: S Jacob; J Machann; K Rett; K Brechtel; A Volk; W Renn; E Maerker; S Matthaei; F Schick; C D Claussen; H U Häring Journal: Diabetes Date: 1999-05 Impact factor: 9.461
Authors: Geraldine Harriman; Jeremy Greenwood; Sathesh Bhat; Xinyi Huang; Ruiying Wang; Debamita Paul; Liang Tong; Asish K Saha; William F Westlin; Rosana Kapeller; H James Harwood Journal: Proc Natl Acad Sci U S A Date: 2016-03-14 Impact factor: 11.205
Authors: Amanda E Brandon; Ella Stuart; Simon J Leslie; Kyle L Hoehn; David E James; Edward W Kraegen; Nigel Turner; Gregory J Cooney Journal: J Endocrinol Date: 2015-12-14 Impact factor: 4.286
Authors: David A Griffith; Daniel W Kung; William P Esler; Paul A Amor; Scott W Bagley; Carine Beysen; Santos Carvajal-Gonzalez; Shawn D Doran; Chris Limberakis; Alan M Mathiowetz; Kirk McPherson; David A Price; Eric Ravussin; Gabriele E Sonnenberg; James A Southers; Laurel J Sweet; Scott M Turner; Felix F Vajdos Journal: J Med Chem Date: 2014-12-11 Impact factor: 7.446
Authors: Francis B Stephens; Benjamin T Wall; Kanagaraj Marimuthu; Chris E Shannon; Dumitru Constantin-Teodosiu; Ian A Macdonald; Paul L Greenhaff Journal: J Physiol Date: 2013-07-01 Impact factor: 5.182
Authors: Karen van Eunen; Sereh M J Simons; Albert Gerding; Aycha Bleeker; Gijs den Besten; Catharina M L Touw; Sander M Houten; Bert K Groen; Klaas Krab; Dirk-Jan Reijngoud; Barbara M Bakker Journal: PLoS Comput Biol Date: 2013-08-15 Impact factor: 4.475